These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18520695)

  • 1. Adherence to bisphosphonate treatment by elderly women.
    Berecki-Gisolf J; Hockey R; Dobson A
    Menopause; 2008; 15(5):984-90. PubMed ID: 18520695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knowledge and health literacy are not associated with osteoporotic medication adherence, however income is, in Arab postmenopausal women.
    Shehadeh-Sheeny A; Eilat-Tsanani S; Bishara E; Baron-Epel O
    Patient Educ Couns; 2013 Nov; 93(2):282-8. PubMed ID: 23994007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.
    Montori VM; Shah ND; Pencille LJ; Branda ME; Van Houten HK; Swiglo BA; Kesman RL; Tulledge-Scheitel SM; Jaeger TM; Johnson RE; Bartel GA; Melton LJ; Wermers RA
    Am J Med; 2011 Jun; 124(6):549-56. PubMed ID: 21605732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
    Hiligsmann M; Rabenda V; Bruyère O; Reginster JY
    Health Policy; 2010 Jul; 96(2):170-7. PubMed ID: 20153543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
    Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
    Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of bisphosphonate therapy in a community setting.
    Feldstein AC; Weycker D; Nichols GA; Oster G; Rosales G; Boardman DL; Perrin N
    Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis and pharmaceutical care].
    Kövér K; Mészáros A
    Acta Pharm Hung; 2012; 82(2):75-9. PubMed ID: 22870780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary non-adherence to bisphosphonates in an integrated healthcare setting.
    Reynolds K; Muntner P; Cheetham TC; Harrison TN; Morisky DE; Silverman S; Gold DT; Vansomphone SS; Wei R; O'Malley CD
    Osteoporos Int; 2013 Sep; 24(9):2509-17. PubMed ID: 23595561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living with urinary incontinence: a longitudinal study of older women.
    Byles J; Millar CJ; Sibbritt DW; Chiarelli P
    Age Ageing; 2009 May; 38(3):333-8; discussion 251. PubMed ID: 19258398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.